Perspective Therapeutics, Inc. (NYSE:CATX) Position Reduced by MetLife Investment Management LLC

MetLife Investment Management LLC trimmed its position in Perspective Therapeutics, Inc. (NYSE:CATX) by 28.7% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 22,228 shares of the company’s stock after selling 8,937 shares during the period. MetLife Investment Management LLC’s holdings in Perspective Therapeutics were worth $71,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in CATX. Nicholson Wealth Management Group LLC lifted its stake in Perspective Therapeutics by 0.4% during the fourth quarter. Nicholson Wealth Management Group LLC now owns 1,609,283 shares of the company’s stock valued at $5,134,000 after purchasing an additional 7,000 shares during the last quarter. Affinity Asset Advisors LLC increased its holdings in shares of Perspective Therapeutics by 160.0% in the fourth quarter. Affinity Asset Advisors LLC now owns 1,300,000 shares of the company’s stock valued at $4,147,000 after buying an additional 800,000 shares in the last quarter. Walleye Capital LLC lifted its position in shares of Perspective Therapeutics by 2,526.2% during the 4th quarter. Walleye Capital LLC now owns 475,792 shares of the company’s stock valued at $1,518,000 after acquiring an additional 457,675 shares during the last quarter. WealthPlan Investment Management LLC boosted its stake in shares of Perspective Therapeutics by 18.2% during the 4th quarter. WealthPlan Investment Management LLC now owns 401,049 shares of the company’s stock worth $1,279,000 after acquiring an additional 61,757 shares in the last quarter. Finally, Jump Financial LLC acquired a new position in shares of Perspective Therapeutics in the 4th quarter worth $688,000. 54.66% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

CATX has been the subject of several analyst reports. Royal Bank of Canada reduced their target price on Perspective Therapeutics from $16.00 to $15.00 and set an “outperform” rating for the company in a report on Thursday, March 27th. Scotiabank began coverage on shares of Perspective Therapeutics in a research note on Friday, March 7th. They set a “sector outperform” rating and a $15.00 price objective for the company. HC Wainwright reissued a “buy” rating and issued a $10.00 target price on shares of Perspective Therapeutics in a research report on Monday, March 31st. Cantor Fitzgerald upgraded shares of Perspective Therapeutics to a “strong-buy” rating in a report on Tuesday, March 4th. Finally, Brookline Capital Management raised shares of Perspective Therapeutics to a “strong-buy” rating in a research note on Monday, March 10th. One research analyst has rated the stock with a hold rating, seven have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat.com, Perspective Therapeutics currently has a consensus rating of “Buy” and an average target price of $12.75.

Insider Transactions at Perspective Therapeutics

In other Perspective Therapeutics news, CFO Juan Graham bought 33,333 shares of the firm’s stock in a transaction on Friday, March 28th. The stock was bought at an average cost of $2.25 per share, with a total value of $74,999.25. Following the completion of the transaction, the chief financial officer now directly owns 35,354 shares of the company’s stock, valued at approximately $79,546.50. The trade was a 1,649.33 % increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Robert F. Williamson III purchased 38,145 shares of the company’s stock in a transaction dated Monday, March 31st. The shares were acquired at an average price of $2.14 per share, for a total transaction of $81,630.30. Following the purchase, the director now owns 108,982 shares in the company, valued at $233,221.48. The trade was a 53.85 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last ninety days, insiders have purchased 115,696 shares of company stock valued at $256,344. 3.72% of the stock is owned by insiders.

Perspective Therapeutics Trading Down 2.9 %

Perspective Therapeutics stock opened at $2.35 on Friday. The firm’s 50 day moving average price is $2.26 and its two-hundred day moving average price is $4.02. Perspective Therapeutics, Inc. has a twelve month low of $1.60 and a twelve month high of $19.05.

Perspective Therapeutics Profile

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.